EDAP TMS S.A. (EDAP)
| Previous close | 7.14 |
| Open | 7.13 |
| Bid | 7.12 x 100 |
| Ask | 0.00 x 0 |
| Day's range | 7.07 - 7.25 |
| 52-week range | 3.60 - 12.09 |
| Volume | |
| Avg. volume | 38,520 |
| Market cap | 262.695M |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.61 |
| Earnings date | 16 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.57 |
GlobeNewswireEDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association (AUA) Annual Meeting
Final results demonstrate a significantly higher salvage treatment free survival rate (STFS) at 30 months of 89.6% in the HIFU-treated arm versus 86.2% in patients who underwent radical prostatectomy (RP) Functional evaluation criteria show better results with respect to urinary continence and erectile function in patients receiving HIFU therapy versus patients receiving RP Final study results were presented during a plenary session of the AUA focused on paradigm-shifting and practice-changing c
Globe NewswireEDAP to Announce First Quarter 2024 Financial Results on May 16, 2024
Company to host conference call and webcast on Thursday, May 16th at 8:30am EDT LYON, France, May 2, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2024, before the markets open on Thursday, May 16th, 2024. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer
- GlobeNewswire
EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting
LYON, France, April 23, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that final results from the HIFI Study, the largest clinical trial ever conducted comparing EDAP’s Focal One robotic high intensity focused ultrasound (HIFU) versus radical prostatectomy (RP) for the treatment of prostate cancer, will be presented during a plenary session at the 119th American Urological Association Annual Meeting (AUA 2024), which is taking place from May 3-
